Sterling Bancorp (STL:NYS): Analytics, Extensive Financial Metrics, and Benchmarks Against Averages and Top Companies Within its Industry
Key Findings: - Unique new report provides deep financial benchmarks for (Sterling Bancorp (STL:NYS) compared to its top competitors and compared to the average for all companies within its primary industry. - Benchmarking study for (Sterling Bancorp ) includes growth forecast for its primary industry to the year 2024.
The purpose of this report is to provide vital corporate-specific benchmarks, comparing the Subject Company to its top competitors (on a company-by-company basis) and to the averages within its primary industry for all key metrics.
This is a unique report containing high-value data. The report begins with a superb overview of the primary industry of the Subject Company, including historical industry revenues, revenue forecasts and CAGR. Then the report moves into industry averages and metrics, then into data specific to the Subject Company, with comparative data for the Subject Company’s top competitors. This report will save countless hours of research and analytical work for the end user.
Core Benefits to Customer: 1) Comprehensive benchmarks for the Subject Company: a. Benchmarked against the leading firms in its primary industry b. Benchmarked against the average for publicly-held companies (U.S.) in its industry. c. This includes financial results, ratios, vital statistics and metrics in one package, including historical and current metrics and averages for 6 years within its primary industry. 2) A snapshot overview of the company’s primary industry, including current and historic revenues and employment, along with a long term forecast for industry growth, with CAGR (compound annual growth rate), employee population and much more. 3) Detailed rankings of the Subject Company against top companies within the industry (U.S.-based firms) for key items including: a. Approximate market capitalization b. Employees c. Revenues d. Net income e. 3-Year revenue growth (%) f. 3-Year income growth (%) g. Return on assets (%) h. Return on equity (%) i. Return on invested capital (%) 4) Leading companies-profiles of the Subject Company as well as profiles of top competitors within the industry
This report is part of the Plunkett’s Corporate Benchmarks series, published by the Plunkett Analytics unit of Plunkett Research, Ltd. Plunkett Research has unique capabilities for creating corporate and industry information, due to the industry and company research that we have been conducting for more than 20 years. Our access to hundreds of industry tables from our own databases, along with our databases of public and private company information, industry trends analysis and other resources, have been utilized in preparing this report. Similar reports are available for all significant, U.S. publicly-held firms.
Designed to benefit: - Analysis and Financial Modeling -Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants
Companies Profiled: - JP Morgan Chase & Co Inc - Wells Fargo & Co - Bank of America Corp - Citigroup Inc - Capital One Financial Corp - US Bancorp - Bank of New York Mellon Corp - PNC Financial Services Group Inc - BB&T Corporation - Discover Financial Services
Our reports have been used by over 10K customers, including:
Seborrhea - Pipeline Review, H2 2019 Summary The latest Pharmaceutical and Healthcare disease pipeline guide Seborrhea - Pipeline Review, H2 2019, provides an overview of the Seborrhea (Dermatology) pipeline landscape. Seborrhea is form of skin eczema that mainly affects scalp, ears, face,...
Aplastic Anemia - Pipeline Review, H2 2019 Summary The latest Pharmaceutical and Healthcare disease pipeline guide Aplastic Anemia - Pipeline Review, H2 2019, provides an overview of the Aplastic Anemia (Hematological Disorders) pipeline landscape. Aplastic anemia is a syndrome of bone marrow...
Interleukin 1 - Pipeline Review, H1 2020 Summary Interleukin 1 (IL1) pipeline Target constitutes close to 24 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Interleukin 1 (IL1) - Pipeline Review, H1 2020,...
"Anesthetic Effect - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020" report offers comprehensive insights on marketed and Phase III products for Anesthetic Effect. The marketed products information covers their product details, patents (US & EU), historical and forecasted sales till 2023. It further provides the marketed...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.